sunitinib viasana kõvakapsel
viasana uab - sunitiniib - kõvakapsel - 25mg 30tk
sunitinib viasana kõvakapsel
viasana uab - sunitiniib - kõvakapsel - 50mg 30tk
sunitinib viasana kõvakapsel
viasana uab - sunitiniib - kõvakapsel - 12,5mg 30tk
sunitinib teva kõvakapsel
teva b.v. - sunitiniib - kõvakapsel - 50mg 28tk; 50mg 30tk
sunitinib teva kõvakapsel
teva b.v. - sunitiniib - kõvakapsel - 12,5mg 30tk
sunitinib teva kõvakapsel
teva b.v. - sunitiniib - kõvakapsel - 25mg 28tk
opzelura kreem
incyte biosciences distribution b.v. - ruksolitiniib - kreem - 15mg 1g 60g 1tk
sutent
pfizer limited - sunitiniib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastilised ained - gastrointestinal stromal tumour (gist)sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib mesilate treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. experience with sutent as first-line treatment is limited (see section 5.
yescarta
kite pharma eu b.v. - axicabtagene ciloleucel - lymphoma, follicular; lymphoma, large b-cell, diffuse - antineoplastilised ained - yescarta is indicated for the treatment of adult patients with diffuse large b cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) dlbcl and primary mediastinal large b cell lymphoma (pmbcl), after two or more lines of systemic therapy. yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (fl) after three or more lines of systemic therapy.
inlyta
pfizer europe ma eeig - aksitiniib - kartsinoom, neerurakk - protein kinase inhibiitorid - inlyta is indicated for the treatment of adult patients with advanced renal cell carcinoma (rcc) after failure of prior treatment with sunitinib or a cytokine.